These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29984508)

  • 1. Waldenstrom macroglobulinaemia manifesting as acquired von Willebrand syndrome.
    Mohamed M
    Intern Med J; 2018 Jul; 48(7):888-891. PubMed ID: 29984508
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acquired von Willebrand's disease].
    Berentsen S; Hammerstrøm J
    Tidsskr Nor Laegeforen; 1993 May; 113(12):1463-5. PubMed ID: 8332973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome.
    Coucke L; Marcelis L; Deeren D; Van Dorpe J; Lambein K; Devreese K
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):395-7. PubMed ID: 24469392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia.
    Castillo JJ; Gustine JN; Meid K; Dubeau T; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
    Br J Haematol; 2019 Mar; 184(6):1011-1014. PubMed ID: 29532913
    [No Abstract]   [Full Text] [Related]  

  • 5. Bilateral simultaneous central retinal vein occlusion (CRVO) caused by waldenstrom's macroglobulinaemia with acquired von willebrand's disease.
    Casares PZ; Gillet DS; Verity DH; Rowson NR
    Br J Haematol; 2002 Jul; 118(1):344-7. PubMed ID: 12100172
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.
    Kong D; Li Y; Fu C; Hou M; Yan L; Shang J; Wang Z; Yin J; Yu Z; Wu D
    Leuk Lymphoma; 2022 Feb; 63(2):491-494. PubMed ID: 34668450
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: an option to consider.
    Butelet A; Poulain S; Jeanpierre E; Srour M; Nudel M; Chauvet P; Bauters A; Susen S; Dupont A; de Charette M
    Leuk Lymphoma; 2022 Dec; 63(13):3100-3104. PubMed ID: 36528585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Von Willebrand's disease associated with Waldenström's macroglobulinemia].
    Laurin S; Maheu M
    Union Med Can; 1980 Aug; 109(8):1201-3. PubMed ID: 6782733
    [No Abstract]   [Full Text] [Related]  

  • 9. Waldenström macroglobulinaemia: the key questions.
    D'Souza A; Ansell S; Reeder C; Gertz MA
    Br J Haematol; 2013 Aug; 162(3):295-303. PubMed ID: 23651417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemostatic therapy in a patient with acquired von Willebrand disease and Waldenström disease with plasmapheresis and DDAVP].
    Thies K; Budde U; Hellstern P
    Beitr Infusionsther; 1990; 26():179-82. PubMed ID: 1703824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.
    Federici AB
    Hum Immunol; 2005 Apr; 66(4):422-30. PubMed ID: 15866707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy.
    Lavin M; Ryan K; White B; Byrne M; O'Connell NM; O'Donnell JS
    Haemophilia; 2018 Jan; 24(1):e22-e25. PubMed ID: 29168278
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin.
    Arkel YS; Lynch J; Kamiyama M
    Thromb Haemost; 1994 Oct; 72(4):643-4. PubMed ID: 7878645
    [No Abstract]   [Full Text] [Related]  

  • 14. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.
    Owen RG; Pratt G; Auer RL; Flatley R; Kyriakou C; Lunn MP; Matthey F; McCarthy H; McNicholl FP; Rassam SM; Wagner SD; Streetly M; D'Sa S;
    Br J Haematol; 2014 May; 165(3):316-33. PubMed ID: 24528152
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous gammaglobulin therapy for acquired von Willebrand disease.
    van den Bosch J; Wolters-Geldof MJ; Vasmel WL
    Eur J Haematol; 1998 Apr; 60(4):271-2. PubMed ID: 9579885
    [No Abstract]   [Full Text] [Related]  

  • 16. Waldenstrom's macroglobulinaemia with intracerebral haemorrhage.
    Khan GQ; Hassan DG; Masood T; Khan AR
    J Postgrad Med; 2000; 46(3):187-8. PubMed ID: 11298468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired von Willebrand syndrome: an update.
    Franchini M; Lippi G
    Am J Hematol; 2007 May; 82(5):368-75. PubMed ID: 17133419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance.
    Agarwal N; Klix MM; Burns CP
    Ann Intern Med; 2004 Jul; 141(1):83-4. PubMed ID: 15238389
    [No Abstract]   [Full Text] [Related]  

  • 20. Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
    Eikenboom JC; Tjernberg P; Van Marion V; Heering KJ
    Am J Hematol; 2007 Jan; 82(1):55-8. PubMed ID: 16986130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.